insulin News
Most Popular insulin Story
Insulin drugs could lose $6.1B to biosimilars
What class of drugs is most vulnerable to biosimilar competition? If you said diabetes meds, then you're right. That's because biosimilar insulins and insulin analogues are easy to develop and make,... Read more...
Latest Headlines
- October 14, 2009
- November 12, 2007
- October 23, 2007
- August 30, 2007
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
